Age, yrs, mean (SD)
Female sex, n (%)
|
59.0 (14.9)
14 (53.8)
|
57.4 (18.9)
8 (35.9)
|
50.7 (20.6)
12 (57.1)
|
57.7 (15.0)
14 (61.5)
|
NS
NS
|
Diagnosis
MPA, n (%)
GPA, n (%)
EGPA, n (%)
|
17 (65.4)
5 (19.2)
4 (15.4)
|
10 (76.9)
3 (23.1)
0
|
9 (42.9)
12 (57.1)
0
|
19 (48.7)
16 (41.0)
4 (10.3)
|
0.05
|
ANCA specificity
Anti-MPO, n (%)
Anti-PR3, n (%)
|
23 (88.5)
3 (11.5)
|
11 (84.6)
2 (15.4)
|
9 (42.9)
12 (57.1)
|
24 (61.5)
15 (38.5)
|
0.004
|
Clinical features
Constitutional symptoms, n (%)
Fever, n (%)
Anemia, n (%)
Microhaematuria, n (%)
Renal failure, n (%)
Alveolar haemorrhage, n (%)
Pulmonary infiltrates, n (%)
Pulmonary nodules, n (%)
Mononeuritis multiplex, n (%)
CNS involvement, n (%)
ENT involvement, n (%)
Purpura, n (%)
Arthritis, n (%)
Ocular involvement, n (%)
|
22 (84.6)
15 (57.7)
22 (84.6)
16 (61.5)
16 (61.5)
7 (26.9)
6 (23.1)
2 (7.7)
5 (19.2)
2 (7.7)
6 (23.1)
2 (7.7)
13 (50.0)
0
|
9 (69.2)
5 (38.5)
12 (92.3)
11 (84.6)
9 (69.2)
2 (15.4)
0
3 (23.1)
1 (7.7)
0
2 (15.4)
3 (23.1)
3 (23.1)
1 (7.7)
|
17 (81.0)
11 (52.4)
21 (100)
16 (76.2)
14 (66.7)
6 (28.6)
5 (23.8)
5 (23.8)
4 (19.0)
1 (4.8)
10 (47.6)
5 (23.8)
14 (66.7)
3 (14.3)
|
24 (61.5)
23 (59.0)
29 (74.4)
25 (64.1)
21 (53.8)
13 (33.3)
11 (28.2)
10 (25.6)
6 (15.4)
2 (5.1)
15 (38.5)
4 (10.3)
19 (48.7)
6 (15.4)
|
NS
NS
0.05
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
|
Treatment
Cyclophosphamide, n (%)
Azathioprine, n (%)
Mycophenolic acid, n (%)
Methotrexate, n (%)
Plasmapheresis, n (%)
Rituximab, n (%)
|
18 (69.2)
10 (38.5)
3 (11.5)
0
10 (38.5)
10 (38.5)
|
12 (92.3)
6 (46.2)
3 (23.1)
0
1 (7.7)
2 (15.4)
|
19 (90.5)
9 (42.9)
7 (33.3)
2 (9.5)
3 (14.3)
6 (28.6)
|
29 (74.4)
14 (35.9)
7 (17.9)
10 (25.6)
3 (7.7)
14 (35.9)
|
NS
NS
NS
0.007
0.009
NS
|
Outcome
Follow-up, yrs, median (IQR)
Clinical relapsea, n (%)
Worsening renal function, n (%)
End-stage renal disease, n (%)
-ESRD at baseline, n (%)
-ESRD during follow-up, n (%)
Mortality, n (%)
Mortality related to vasculitis, n (%)
|
5.7 (3.3)
6 (23.1)
0
7 (26.9)
6 (23.1)
1 (3.8)
6 (23.1)
2 (7.7)
|
7.1 (7.5)
4 (30.8)
0
1 (7.7)
0
1 (7.7)
4 (30.8)
3 (23.1)
|
9.6 (7.5)
15 (71.4)
2 (9.5)
3 (14.3)
0
3 (14.3)
5 (23.8)
8 (38.1)
|
8.6 (8.0)
34 (87.2)
3 (7.7)
8 (20.5)
2 (5.1)
6 (15.4)
14 (35.9)
13 (33.3)
|
0.07
<0.001
0.06
NS
0.01
NS
NS
NS
|